Evaluation of Transparency to Improve Good Governance in Pharmaceutical Regulatory Sector of Iran

Background: Improving good governance in the pharmaceutical sector is a valuable priority for improving access to essential medicines. Transparency as a means for good governance was the focus of this study. The objective was to evaluate different sectors of the pharmaceutical regulatory sector of I...

Full description

Saved in:
Bibliographic Details
Main Authors: Yasaman Herandi (Author), Shekoufeh Nikfar (Author), Hossein Bouzarjomehri (Author), Akbar Abdollahiasl (Author)
Format: Book
Published: Shahid Sadoughi University of Medical Sciences, 2020-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_1df81e7ab8f0465493aa412c00a79d24
042 |a dc 
100 1 0 |a Yasaman Herandi  |e author 
700 1 0 |a Shekoufeh Nikfar  |e author 
700 1 0 |a Hossein Bouzarjomehri  |e author 
700 1 0 |a Akbar Abdollahiasl  |e author 
245 0 0 |a Evaluation of Transparency to Improve Good Governance in Pharmaceutical Regulatory Sector of Iran 
260 |b Shahid Sadoughi University of Medical Sciences,   |c 2020-09-01T00:00:00Z. 
500 |a 2538-5070 
500 |a 2538-4716 
520 |a Background: Improving good governance in the pharmaceutical sector is a valuable priority for improving access to essential medicines. Transparency as a means for good governance was the focus of this study. The objective was to evaluate different sectors of the pharmaceutical regulatory sector of Iran from the aspect of transparency. Awareness of the current situation may assist policymakers in making the right decisions. Methods: The aim of this methodology was to present only quantitative measurement but to gather qualitative information as well. The study was carried from November 2016 to July 2017. The questionnaires of the assessment instrument, which the World Health Organization (WHO) produced for measuring transparency in the public pharmaceutical sector, was used. The interviewees were among managers and staff at different levels of the Food and Drug Administration (IFDA) of Iran and its clients. Results: Medicines registration and distribution of medicines' scores in the 10-point rating system means that they are minimally vulnerable to corruption. Besides, medicine promotion control and procurement of medical products got an acceptable score, which means that they are marginally vulnerable to corruption. On the other hand, qualitative findings and observation of the evidence presented by key informants proved the sufficient legal capacity for transparency in almost all sections. The controversial issue was the 'conflict of interests,' which was not anticipated in some cases. Conclusion: It is valuable to know if Iran's medicine regulatory sector is transparent In order to improve good governance, transparency should be maximized in all sectors, and this is possible by implementing mechanized actions and online tools. 
546 |a EN 
690 |a pharmacy administration 
690 |a drug and narcotic control 
690 |a evaluation 
690 |a pharmacoeconomics 
690 |a iran 
690 |a Medicine 
690 |a R 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n Journal of Evidence Based Health Policy, Management & Economics, Vol 4, Iss 3, Pp 197-208 (2020) 
787 0 |n http://jebhpme.ssu.ac.ir/article-1-284-en.html 
787 0 |n https://doaj.org/toc/2538-5070 
787 0 |n https://doaj.org/toc/2538-4716 
856 4 1 |u https://doaj.org/article/1df81e7ab8f0465493aa412c00a79d24  |z Connect to this object online.